Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in gastric parietal cells.
## Primary Indications
* Gastroesophageal reflux disease (GERD) - erosive esophagitis and symptomatic GERD
* Healing of NSAID-associated gastric ulcers
* H. pylori eradication (in combination with antibiotics)
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
## Adult Dosing
* **GERD (Erosive Esophagitis):** 40 mg orally or intravenously once daily for up to 8 weeks. A subsequent 8-week course may be considered.
* **GERD (Symptomatic):** 20 mg orally once daily. May increase to 40 mg once daily if symptom relief is inadequate.
* **Healing of Gastric Ulcers:** 40 mg orally once daily for 4 to 8 weeks.
* **H. pylori Eradication:** 40 mg orally twice daily for 7 to 14 days in combination with amoxicillin and clarithromycin, or clarithromycin and metronidazole.
* **Pathological Hypersecretory Conditions:** Starting dose is typically 40 mg orally or intravenously twice daily. Doses may be adjusted based on clinical response. Doses up to 240 mg daily have been administered intravenously.
**Maximum Daily Dose:** Generally 40 mg orally once daily for GERD. For hypersecretory conditions, higher doses may be used, with IV administration up to 240 mg daily divided into doses.
## Pediatric Dosing
Dosing varies significantly by indication and age. Consult specific pediatric guidelines or prescribing information.
* **GERD (Erosive Esophagitis, ages 5-16 years):** 20 mg orally once daily for up to 8 weeks.
* **GERD (Erosive Esophagitis, ages 1-5 years):** 20 mg orally once daily for up to 8 weeks.
* **GERD (Symptomatic, ages 5-16 years):** 20 mg orally once daily.
**Note:** Safety and efficacy for other indications in pediatric patients are not established.
## Dose Adjustments
* **Hepatic Impairment:** Maximum daily dose of 20 mg orally.
* **Renal Impairment:** No dose adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
## Adverse Effects
Common: Diarrhea, headache, dizziness, abdominal pain, nausea, flatulence.
Long-term use (≥1 year) may be associated with an increased risk of:
* Fractures (hip, wrist, spine)
* Clostridium difficile infection
* Vitamin B12 deficiency
* Hypomagnesemia
## Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors (e.g., atazanavir).
* **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. Consider temporary discontinuation of pantoprazole.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. This may affect metabolism of drugs like clopidogrel, although clinical significance is debated.
## Monitoring
* **Magnesium levels:** Monitor periodically, especially with prolonged therapy (>3 months) or concurrent diuretic use.
* **Vitamin B12 levels:** Monitor periodically with prolonged therapy.
* **Bone density:** Consider monitoring in patients at risk for osteoporosis, especially with long-term PPI use.
* **Clinical response:** Monitor for symptom improvement and healing of esophageal erosions or ulcers.
## Clinical Pearls
* Pantoprazole is available in both oral and intravenous formulations.
* Oral pantoprazole is generally taken once daily, 30-60 minutes before breakfast.
* Do not crush or chew delayed-release tablets.
* When used for H. pylori eradication, ensure all components of the regimen are administered for the full duration.
* Long-term use of PPIs should be reserved for patients who require it, and the lowest effective dose should be used.
---
**Disclaimer:** This information is intended as a quick reference and does not replace the need to consult the most current official prescribing information, institutional protocols, or clinical guidelines before making any prescribing decisions.
